相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
Karen A. Autio et al.
CLINICAL CANCER RESEARCH (2020)
Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue
Danique Giesen et al.
CLINICAL CANCER RESEARCH (2020)
Programmable Bivalent Peptide-DNA Locks for pH-Based Control of Antibody Activity
Wouter Engelen et al.
ACS CENTRAL SCIENCE (2020)
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody
Martina Geiger et al.
NATURE COMMUNICATIONS (2020)
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
Dinh-Toi Chu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
A coiled-coil masking domain for selective activation of therapeutic antibodies
Vivian H. Trang et al.
NATURE BIOTECHNOLOGY (2019)
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Jun Ishihara et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Intratumoral fate of functional nanoparticles in response to microenvironment factor: Implications on cancer diagnosis and therapy
Jinrong Peng et al.
ADVANCED DRUG DELIVERY REVIEWS (2019)
Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy
Noor Momin et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Hypoxia-Activated PEGylated Conditional Aptamer/Antibody for Cancer Imaging with Improved Specificity
Fang Zhou et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
Chien-Chun Steven Pai et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Qian Chen et al.
NATURE NANOTECHNOLOGY (2019)
CD8+ T cells and IFN-γ induce autoimmune myelofibrosis in mice
Yuan Yao et al.
JOURNAL OF AUTOIMMUNITY (2018)
Immune Responses in the Liver
Paul Kubes et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 36 (2018)
Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury
Yoh Zen et al.
MODERN PATHOLOGY (2018)
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
Li Tang et al.
NATURE BIOTECHNOLOGY (2018)
Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
Chun Gwon Park et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
MMP-Responsive 'Smart' Drug Delivery and Tumor Targeting
Qing Yao et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs
Michael Dougan et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine
Jin-Zhi Du et al.
ACCOUNTS OF CHEMICAL RESEARCH (2018)
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Jeffrey S. Miller et al.
CLINICAL CANCER RESEARCH (2018)
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester et al.
BLOOD (2018)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2017)
Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains
I-Ju Chen et al.
SCIENTIFIC REPORTS (2017)
Glutathione and thioredoxin systems contribute to recombinant monoclonal antibody interchain disulfide bond reduction during bioprocessing
Michael W. Handlogten et al.
BIOTECHNOLOGY AND BIOENGINEERING (2017)
Rationale for anti-CD137 cancer immunotherapy
Amani Makkouk et al.
EUROPEAN JOURNAL OF CANCER (2016)
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy
Yun Yang et al.
MABS (2016)
Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
Eric F. Zhu et al.
CANCER CELL (2015)
Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
Ling Zhang et al.
CLINICAL CANCER RESEARCH (2015)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ
Yin Guo et al.
JOURNAL OF IMMUNOLOGY (2015)
A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases
Lisa Sandersjoo et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
Shihao Chen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Side Effects of Cytokines Approved for Therapy
Brian A. Baldo
DRUG SAFETY (2014)
Localized Immunotherapy via Liposome-Anchored Anti-CD137+IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
Brandon Kwong et al.
CANCER RESEARCH (2013)
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Luc R. Desnoyers et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy
Jessica Ann Chacon et al.
ONCOIMMUNOLOGY (2013)
The First Generation of ß-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy
Thibaut Legigan et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Photocontrolled Targeted Drug Delivery: Photocaged Biologically Active Folic Acid as a Light-Responsive Tumor-Targeting Molecule
Nien-Chu Fan et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases
Oran Erster et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Acid-Labile Traceless Click Linker for Protein Transduction
Kevin Maier et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Immunotherapy of Cancer with 4-1BB
Dass S. Vinay et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models
Simon N. Wood
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2011)
Hydrogen Peroxide Activated Matrix Metalloproteinase Inhibitors: A Prodrug Approach
Jody L. Major Jourden et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Proligands with protease-regulated binding activity identified from cell-displayed prodomain libraries
Jerry M. Thomas et al.
PROTEIN SCIENCE (2009)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg et al.
NATURE REVIEWS CANCER (2008)
Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice
Liguo Niu et al.
JOURNAL OF IMMUNOLOGY (2007)
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
CA Klebanoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Why do cancers have high aerobic glycolysis?
RA Gatenby et al.
NATURE REVIEWS CANCER (2004)
分享论文
